Prostate Cancer News
Here are some updates in the world of radiogland therapy, prostate cancer treatments, research, and more.
Lutetium Lu 177 Vipivotide Tetraxetan (PLUVICTO) Is an NCCN Recommended Option for Patients With mCRPC
I'm excited to share that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend lutetium Lu 177 vipivotide tetraxetan (PLUVICTO®) as an NCCN Category 2A* treatment option for patients without prior taxane-based chemotherapy. This NCCN recommendation further reinforces clinical benefit demonstrated in the phase 3 PSMAfore trial. Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO) is approved for patients with PSMA+ mCRPC after only 1 ARPI. I would love to set up a time to discuss this new option for your patients.
NCCN Category 2A* recommended, useful in certain circumstances, for mCRPC patients.
Source: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 16, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.
Pluvicto Moves into Earlier Treatment Stages - June 2025
A Phase III trial called PSMAddition evaluated Pluvicto (lutetium‑177‑PSMA‑617) combined with hormone therapy in men with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). Initial findings show a statistically significant improvement in radiographic progression-free survival (rPFS) and a trend toward better overall survival compared to hormone therapy alone
Source: Novartis News
New Combination Data for Xofigo - June 2025
At ASCO 2025, updated trial results revealed that pairing Xofigo (radium‑223) with enzalutamide significantly improved PSA responses and rPFS in men with bone-metastatic metastatic castration-resistant prostate cancer (mCRPC), compared to enzalutamide alone
Source: Oncology News Central
Pluvicto Gains FDA Label Expansion for Earlier Use - March 2025
The FDA granted an expanded indication for Pluvicto (lutetium‑177‑PSMA‑617), allowing its use in men with PSMA-positive metastatic castration-resistant prostate cancer who are hormone therapy-resistant but chemotherapy-naïve. The decision is based on the pivotal PSMAfore Phase III trial, which demonstrated that Pluvicto more than doubled radiographic progression-free survival (rPFS)—11.6 months vs. 5.6 months—compared to a change in androgen receptor pathway inhibitors
Source: Cancer Network
